Curaleaf reported a larger-than-expected quarterly loss. Adjusted EPS was -C$0.1729, compared with an estimate of -C$0.15. The miss breaks a four-quarter stretch in which the company beat estimates three times.
Curaleaf Holdings Inc. (TSX: CURA) reported results for the quarter ended September 30, 2026, after markets closed on November 3. Calendar data shows EPS of -C$0.1729, 15.27% below the -C$0.15 estimate. The data provided does not include actual revenue or margins for the quarter, so EPS is the clearest measure of the results. Curaleaf’s latest loss follows two quarters with positive EPS that beat estimates, but its trailing-twelve-month EPS remains negative. For Canadian investors, the results underline how difficult it is to assess the path to sustained profitability amid volatile earnings and ongoing losses.
Recent earnings trend
Curaleaf Holdings Inc.
CURA.TO
CURA.TO
Curaleaf Holdings Inc.
WealthAwesomeMarket cap
$3.36B
52W high
$20.93
52W low
$7.77
1W change
-1.17%
Beta
1.76
Analyst Price Targets
Based on analyst covering CURA · as of Nov 10, 2026
Wall Street analysts forecast CURA stock price to rise 54.4% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$19.58
+54.4% Upside
Previously C$19.64 on Nov 9, 2026
Current Price
C$12.68
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CURA's historical volatility
30-Day Vol
64.3%
Annualized
90-Day Vol
60.6%
Annualized
Trend (90d)
-26.3%
Annualized drift
90d Mean
C$11.54
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$12.29 | C$9.84 – C$15.34 |
| 60 trading days | C$11.91 | C$8.70 – C$16.30 |
| 90 trading days | C$11.54 | C$7.86 – C$16.95 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Analyst coverage: 1 analyst(s) cover this name; upcoming EPS consensus is available.
Beat estimates in 3 of the last 4 comparable quarter(s).
| Fiscal period | Report date | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| 2026-12-31 | 2027-02-25 | — | -0.1500 | — |
| 2026-09-30 | 2026-11-03 | -0.1729 | -0.1500 | -15.3% |
| 2026-06-30 | 2026-08-05 | 0.0700 | -0.2400 | +129.2% |
| 2026-03-31 | 2026-05-04 | 0.2900 | -0.2700 | +207.4% |
| 2025-12-31 | 2026-02-26 | -0.0500 | -0.0900 | +44.4% |
| 2025-09-30 | 2025-11-04 | -0.1900 | -0.2400 | +20.8% |
Investor takeaway: CURA missed its latest EPS estimate after beating estimates in three of its previous four comparable quarters. The supplied calendar lists revenue consensus of US$345.60 million from one analyst, but no actual revenue figure, so it’s not possible to assess a revenue surprise. Curaleaf’s EPS (TTM) is -0.07 and its profit margin is -0.76%. Analyst targets suggest substantial upside from the last close, while Wealth Awesome’s statistical 90-day model has a lower average forecast and wide ranges. Neither measure guarantees a return. Investors should consider the loss, the limited analyst sample and the volatility of the cannabis sector.
EPS: -C$0.1729
Curaleaf missed the -C$0.15 estimate by 15.27%. It beat estimates in three of its last four comparable quarters, but its latest EPS was negative.
Bull case
Curaleaf has beaten EPS estimates in three of its last four comparable quarters, including periods with positive reported EPS in March and June 2026. A company update also pointed to higher revenue and improved profitability in the third quarter, though the supplied data does not include figures to measure that improvement. Analysts’ average target is C$19.58, well above the last close of C$12.68.
Bear case
The latest EPS miss followed two quarters of positive results, and Curaleaf remains unprofitable on a trailing-twelve-month basis. The next-period consensus comes from one analyst, so it offers only a limited view of expectations. Wealth Awesome’s model puts 30-day volatility at 64.3% and its average forecast below the current price. Cannabis businesses also face operating and regulatory challenges. The information provided does not show whether recent strategic moves will lead to lasting earnings growth.
Analysis
Curaleaf reported EPS of -C$0.1729 for the quarter ended September 30, against an estimate of -C$0.15—a 15.27% miss. Before this quarter, EPS was C$0.07 in June and C$0.29 in March, both above estimates. In December 2025, EPS was -C$0.05, compared with an estimate of -C$0.09. Curaleaf beat estimates in three of its last four comparable quarters, but the latest loss shows that its progress toward profitability has not been steady.
The supplied earnings record includes 26 quarters of actual and estimated results. The recent earnings trend table and chart provide more history. No actual revenue or margin figures were supplied for this quarter, so we can’t determine whether revenue beat or missed expectations. Market coverage cited a company update describing higher third-quarter revenue and improved profitability, but without the underlying figures, it can’t replace a direct comparison with estimates. Visit the CURA stock page for more company information.
Analysis
Analyst data gives Curaleaf an average target of C$19.58, compared with a last close of C$12.68. That implies 54.4% upside to the average target. The data labels the consensus bullish based on the target-price comparison, but it does not include a formal rating for the Canadian listing. Analyst targets are estimates, not promised returns, and can change as assumptions shift. See the analyst ratings section for details.
Wealth Awesome price forecast: This statistical model is not financial advice. Its 90-day average forecast is C$11.54, below the C$12.68 reference price from November 9, 2026. The model’s 68% range is C$7.86–C$16.95, and its 95% range is C$5.35–C$24.90. It estimates annualized drift of -26.3% and 30-day volatility of 64.3%. The wide ranges point to substantial uncertainty, not a guaranteed direction. See the price prediction section for details.
Analysis
For the next reported period, the supplied calendar lists EPS consensus of -C$0.21 and revenue consensus of US$345.60 million, each based on one analyst. The EPS estimate is unchanged from 30 days ago, with one downward revision and no upward revisions. The same data lists year-over-year EPS growth of -10.2%, based on year-ago EPS of -C$0.19, and estimated revenue growth of 7.9%. With just one analyst contributing, these figures offer a limited view of expectations.
Curaleaf’s fundamentals snapshot shows EPS (TTM) of -0.07 and a profit margin of -0.76%. The key question is whether revenue growth can lead to lasting profitability, but the figures provided don’t answer that. The last close was below the 50-day moving average of C$13.44 and above the 200-day average of C$12.49. It was also well below the 52-week high of C$20.93. These figures describe recent trading, not future performance. Canadian investors should weigh the earnings record, limited analyst coverage and wide model ranges together rather than rely on any single target.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
